Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

Asia Pac IPO & Placement Research, China biotech

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

CanSino Biologics  / Equity Capital Markets

CanSino Biologics, a vaccine-focused biotech company, is planning to seek up to USD 150 million via a listing on the Hong Kong Stock Exchange.
In this insight, we will look at the following topics:
<ul>
<li>CanSino's vaccine pipeline. </li>
<li>Differentiating factor of individual vaccine candidates.</li>
<li>The addressable market for individual vaccine candidates.</li>
<li>The company's founders and investors.</li>
</ul>
We will discuss the company's valuation in our next insight.

CanSino Biologics, a vaccine-focused biotech company, is planning to seek up to USD 150 million via a listing on the Hong Kong Stock Exchange.
In this insight, we will look at the following topics:

CanSino's vaccine pipeline. 
Differentiating factor of individual vaccine candidates.
The addressable market for individual vaccine candidates.
The company's founders and investors.

We will discuss the company's valuation in our next insight.

CanSino Biologics (康希诺) IPO: Promising Pre-Clinical Results but Vaccine Scandal Weighs (Part 1)

China

CanSino Biologics Inc. develops and manufactures biological vaccine products. The Company discovers quadrivalence meningococcal conjugate, pneumococcal polysaccharide, and adenovirus vector-based tuberculosis vaccines for human use. CanSino Biologics serves customers worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

CanSino Biologics (6185 HK)

CanSino Biologics (康希诺) IPO: Promising Pre-Clinical Results but Vaccine Scandal Weighs (Part 1)

CanSino Biologics, a vaccine-focused biotech company, is planning to seek up to USD 150 million via a listing on the Hong Kong Stock Exchange. In...

Ke Yan, CFA, FRM

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)